More on BIIB
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $201.96 |
|
|||
| Open | $202.53 | ||||
| 52 Wk High | $333.65 | ||||
| 52 Wk Low | $223.02 | ||||
| Day High | $218.06 | ||||
| Day Low | $202.53 | ||||
| P/E | 27.66 | ||||
| EPS | $7.81 | ||||
| Volume | 2,374,525 | ||||
- International Regulatory Pathways Have Supported Drug Development Across Biotech and Pharma
- Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis
- Biogen (BIIB) Reiterated at Overweight by Cantor Fitzgerald: Advancing with BIIB080
- Needham Reiterates Buy Rating on Biogen (BIIB)
- Biogen to acquire RayThera for up to $1 billion
- Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc.
- Biogen (BIIB) PT Lowered to $221 at Mizuho
- Form 4 BIOGEN INC. For: Jun 09 Filed by: HAWKINS WILLIAM A
- Form 4 BIOGEN INC. For: Jun 09 Filed by: SHERWIN STEPHEN A
- Form 4 BIOGEN INC. For: Jun 09 Filed by: Rowinsky Eric K
Entities mentioned with BIIB
- Twitter | View Related Stories »
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Definitive Agreement | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Options | View Related Stories »
- Show More...
